Option Care Has Been Selected as a National Provider of CUVITRUTM

BANNOCKBURN, Ill.--()--Option Care Enterprises, Inc., one of the nation’s leading providers of home and alternate treatment site infusion services, has been selected as a contracted provider of a new 20% formulation of subcutaneous immunoglobulin (SCIG) therapy for primary immunodeficiency (PI). CUVITRU™ [Immune Globulin Subcutaneous (Human), 20% Solution] is manufactured by Shire plc.

CUVITRU™ recently was approved by the U.S. Food and Drug Administration to treat adult and pediatric patients two years and older with PI, a group of more than 300 genetic disorders in which part of the body’s immune system is missing or functions improperly.

“Option Care has a proven track record of providing compassionate, high-quality clinical care in the home or at alternate treatment sites to patients undergoing therapy for a variety of complex conditions, including those with primary immunodeficiency,” said Lisa Betts, Vice President, Specialty Programs, Option Care. “As one of the largest national providers of immunoglobulin therapy, we are pleased to offer CUVITRU™ to support primary immunodeficiency patients as we continue to spread awareness and improve treatment options.”

Immunoglobulin (IG) is a lifelong therapy provided to prevent recurrent infections in patients with PI, which affects as many as six million people worldwide.

Option Care has a staff of more than 1,800 clinical experts, including pharmacists and more than 1,200 infusion nurses. This multidisciplinary team of specially trained clinicians provides individualized patient care plans, clinical monitoring of each infusion and comprehensive patient and caregiver education. For more information, call Option Care’s IG Specialty Center of Excellence at 1-877-974-4844 or fax 877-974-4845.

About Option Care

Option Care Enterprises, Inc. (Option Care) is one of the nation’s largest and most trusted providers of home and alternate treatment site infusion services. An industry leader, the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s more than 1,800 clinicians – including pharmacists, nurses and dietitians – are able to provide home infusion service coverage for nearly all acute and chronic patients across the United States. Learn more at www.OptionCare.com.

Contacts

for Option Care
Lauren Kotarski, 312-558-1770
LKotarski@pcipr.com

Release Summary

Option Care Enterprises, Inc. has been selected as a contracted provider of a new 20% formulation of subcutaneous immunoglobulin (SCIG) therapy for primary immunodeficiency (PI), CUVITRU™

Contacts

for Option Care
Lauren Kotarski, 312-558-1770
LKotarski@pcipr.com